about
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjectsVasculogenesis in infantile hemangioma.A switch in Notch gene expression parallels stem cell to endothelial transition in infantile hemangioma.Propranolol targets the contractility of infantile haemangioma-derived pericytes.Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression.AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation.VEGFR-1 mediates endothelial differentiation and formation of blood vessels in a murine model of infantile hemangioma.SOCS3 is an endogenous inhibitor of pathologic angiogenesis.Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangiomaα6-Integrin is required for the adhesion and vasculogenic potential of hemangioma stem cellsEGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells.Pericytes from infantile hemangioma display proangiogenic properties and dysregulated angiopoietin-1Cooperation between human fibrocytes and endothelial colony-forming cells increases angiogenesis via the CXCR4 pathway.Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma.Ponatinib Combined With Rapamycin Causes Regression of Murine Venous MalformationA xenograft model for venous malformationSignaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosisConstitutive Active Mutant TIE2 Induces Enlarged Vascular Lumen Formation with Loss of Apico-basal Polarity and Pericyte RecruitmentConstitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation
P50
Q27333126-97F21BE0-75AF-4A10-9079-1FB62F36D2B8Q33607327-07E594E5-397B-4568-9157-E2DA6522941EQ33756156-22490AEF-D7F2-426C-9B50-05CC87053E72Q34323894-1725AC27-12E5-416B-97FC-35CE1E8384AFQ34555267-209F38D7-9265-4ECE-B777-F603C73F341FQ35196528-DA2153B9-D7ED-4399-829C-5C3A3AA581A9Q35474223-70DEF04D-A7A6-47E7-9A06-787077744C33Q36305360-F92246D5-7F30-47B9-A08B-6866E9D9812CQ36995485-E4A9AD54-1D53-47FE-ABDF-F27EC6B01160Q37620426-748882F2-661D-453B-A96B-A77BB7719C79Q38734229-E7ACD465-D80E-4882-A961-B82E4E49E523Q42238341-266D4D58-2FCA-4AEA-A142-BE4332E246FAQ53478465-47E97778-579D-461C-86E7-26C1D9913128Q55262749-5B21D496-B60F-4646-9317-B6E61BC99DFEQ64230542-2A70A616-2BE4-4A73-A00A-73CDA2554406Q88770307-C7472704-3D74-4D07-9832-DFCCD87FAE83Q91689273-45A6585B-BDBC-42DF-9B12-D6F137CDB649Q92882879-A3583C14-FA85-446D-B0E5-8E9F7AF2A6B9Q94462392-EA082CF5-A390-493D-B0EC-7FB67ED6B819
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elisa Boscolo
@ast
Elisa Boscolo
@en
Elisa Boscolo
@es
Elisa Boscolo
@nl
type
label
Elisa Boscolo
@ast
Elisa Boscolo
@en
Elisa Boscolo
@es
Elisa Boscolo
@nl
prefLabel
Elisa Boscolo
@ast
Elisa Boscolo
@en
Elisa Boscolo
@es
Elisa Boscolo
@nl
P106
P21
P31
P496
0000-0002-6996-0419